Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Agenus Inc.

< Previous 1 2 3 Next >
Agenus Completes Enrollment in Randomized Phase 2 Clinical Trial of Botensilimab/Balstilimab in Advanced Colorectal Cancer
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus To Host BOT/BAL Program Update at ESMO 2023
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus to Participate in September Investor Conferences
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus Prioritizes Resources to Accelerate Registration and Commercialization of BOT/BAL Program in Multiple Cancers
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus Reports Second Quarter 2023 Results
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus Botensilimab/Balstilimab Data Update in Sarcomas Selected for Oral Presentation at ESMO 2023
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus Expands Executive Leadership Team
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus Presents Positive Efficacy and Safety Outcomes for AGEN2373 at ASCO
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus Provides Corporate Update and First Quarter 2023 Financial Results
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus Receives Fast Track Designation for Botensilimab and Balstilimab in Colorectal Cancer
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus Announces Dividend of 5 Million Shares of MiNK Therapeutics
From Agenus Inc.
Via Business Wire
Tickers AGEN INKT
Agenus’ Botensilimab in Combination with Balstilimab Shows 33% Durable Responses in Ovarian Cancer
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus Reports Fourth Quarter and Full Year 2022 Financial Results and Outlines 2023 Objectives
From Agenus Inc.
Via GlobeNewswire
Tickers AGEN
Agenus Cancels Conference Call to Discuss the Company’s Minority Cash Holdings at SVB in Light of Government’s SVB Deposit Access Announcement
From Agenus Inc.
Via GlobeNewswire
Tickers AGEN
Agenus Schedules Conference Call to Discuss the Company’s Minority Cash Holdings at SVB
From Agenus Inc.
Via GlobeNewswire
Tickers AGEN
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2022 Financial Report
From Agenus Inc.
Via GlobeNewswire
Tickers AGEN
Agenus to Present Botensilimab Data in Oral Plenary Session at the Society of Gynecologic Oncology 2023 Annual Meeting on Women’s Cancer
From Agenus Inc.
Via GlobeNewswire
Tickers AGEN
Agenus to Participate in February Investor Conferences
From Agenus Inc.
Via GlobeNewswire
Tickers AGEN
Agenus Presents Clinical Data Demonstrating Durable Responses of Botensilimab/Balstilimab Combination in Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI
From Agenus Inc.
Via GlobeNewswire
Tickers AGEN
Agenus to Participate at B Riley Securities’ 2023 Virtual Oncology Conference
From Agenus Inc.
Via GlobeNewswire
Tickers AGEN
Agenus to Present Botensilimab Data at Late-Breaking Oral Session at ASCO-GI
From Agenus Inc.
Via GlobeNewswire
Tickers AGEN
Agenus Data at CTOS 2022 Highlight Durable Clinical Responses of Botensilimab / Balstilimab Combination in Advanced Sarcoma
From Agenus Inc.
Via GlobeNewswire
Tickers AGEN
Agenus to Participate at 5th Annual Evercore ISI HealthCONx Conference
From Agenus Inc.
Via GlobeNewswire
Tickers AGEN
Agenus Data at SITC 2022 Highlight Durable Responses of Botensilimab / Balstilimab Combination in Nine Different Treatment-Resistant Cancers
From Agenus Inc.
Via GlobeNewswire
Tickers AGEN
Agenus Provides Corporate Update and Third Quarter 2022 Financial Report
From Agenus Inc.
Via GlobeNewswire
Tickers AGEN
Agenus to Provide Corporate Update and Third Quarter 2022 Financial Report
From Agenus Inc.
Via GlobeNewswire
Tickers AGEN
GSK’s older adult RSV vaccine candidate, containing Agenus’ QS-21 STIMULON™, shows 94.1% reduction in severe RSV disease and overall vaccine efficacy of 82.6% in pivotal trial
From Agenus Inc.
Via GlobeNewswire
Tickers AGEN
VBI Vaccines and Agenus Announce Collaboration to Evaluate VBI-1901 in Combination with Anti-PD-1 Balstilimab in a Phase 2 Study in Primary Glioblastoma Patients
From Agenus Inc.
Via GlobeNewswire
Tickers AGEN VBIV
Agenus to Host “The Road Taken” R&D Event on November 12, 2022
From Agenus Inc.
Via GlobeNewswire
Tickers AGEN
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.